Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.

Blood Cancer J · 2026 · PMC13319122 · PMID 42098067

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

did not reach statistical significanceno p-value reported

Although this difference did not reach statistical significance, the data indicate a clear trend toward enhanced activity with the combination.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.